Podcasts about Grade

Bei hitzigen Debatten um Geschlechter, sexuelle Vorlieben oder Glaubensfragen werde die Natur gern als Legitimation für unterschiedlichste Überzeugungen herbeigezogen, ärgert sich Frank Zachos. Zum Beispiel wenn es um die Frage geht: Ist gleichgeschlechtliche Sexualität etwas Natürliches oder nicht? Der Kieler Zoologe leitet die Säugetier-Sammlung am Naturhistorischen Museum in Wien und weiß: Gleichgeschlechtlicher Sex kommt in der Natur ständig vor, etwa bei 1500 uns bisher bekannten Arten, vor allem Säugetieren. Er sei also mitnichten „widernatürlich“. Daraus Schlüsse für unser moralisches Handeln zu ziehen, sei aber gefährlich, warnt Zachos. In seinem Buch „Die Natur kennt feine Grade“ und im Gespräch mit Andrea Schwyzer erklärt er, warum Tiere überhaupt gleichgeschlechtlichen Sex haben (wegen der Fortpflanzung auf jeden Fall nicht), was hinter dem schwierigen Begriff „Menschenrassen“ steckt und was wir von der Natur tatsächlich lernen können.

FC Cincy roll up north beating Montreal 3-1 behind stellar performances from Engel, Luca, and Evander.The offense appears to be rounding in the form and the shuffled back line has now put in back to back strong performances.Listen up as Adam K returns to break down the performance and Adam W listens! @TheKingAdRock73 @NinoOne @sbucks67 @crackityFC @ComeOnYouFCC @fccincinnati @Zuhause513 @MLS #AllForCincy #FCCincy #YAL #WestEndBoys

Ed, Rob, and Jeremy took some time from Thursday's BBMS to look at the Orioles' first 81 games and hand down a grade for the team's first half. Is the only fair grade an ‘F'? Or is an ‘incomplete' more apt because of the injuries?

Douwe Kiela, Founder and CEO of Contextual AI, discusses why RAG isn't obsolete despite massive context windows, explaining how RAG 2.0 represents a fundamental shift to treating retrieval-augmented generation as an end-to-end trainable system. Subscribe to the Gradient Flow Newsletter

Send us a textA 15-year-old Elvis Tribute Artist that many feel is Elvis reincarnated but looks like Joaquin Phoenix! He is the only singer in his family. The attraction started in second grade after his best friend dared him to dress up as Elvis for Halloween, which began the love affair for the King of Rock n Roll. Aiden also sings Johnny Cash, Josh Turner and a couple others but Elvis is his niche. He says, Elvis is a friend of his that he never got to meet and since 2nd Grade he has been singing his songs that began with “Jailhouse Rock.” Aiden spends an hour every day practicing Elvis's music. He states he has watch every single video on YouTube that Elvis has watched to perfect his mannerisms and movement and some of these moves come natural to Aiden. He has jumpsuits made specifically for him along with the replica clothes and he completely embraces this vintage look and mentions; he was born in the wrong era!Being part of a big competition in Memphis in the Big “little” King Division, he will be performing in the Graceland tent very soon, but Aiden really wants to be the Ultimate Elvis and has been to Tupelo, MS many times and performed right outside the birthplace of Elvis! What is next? VEGAS? Steve Pennington is his vocal coach for over the past year and half, and one Aiden believes in him in which the results speak for themselves. Pennington is the one to credit for posting his videos and putting the naysayers at bay that believed Aiden was lip synching by posting an A Capella video. How is he handling all the notoriety from his VIRAL videos? He tells us what long term plans are, and he has a plan B too! What does a teenager away from being Elvis? He ends with a beautiful story of the impact he has had on others.  Aiden Joiner Links:Join the Facebook Group: https://www.facebook.com/groups/386781849478323Instagram: https://www.instagram.com/aiden_joiner/?hl=enWatch Aiden's Tik Tok Videos: https://www.tiktok.com/@santasteve24 Before the Lights Links:Website: https://www.tommycanale.com/beforethelights-episodesGet Tommy a Glass of Vino: https://www.buymeacoffee.com/beforethelightsSupport the showFollow the show on Instagram: https://www.instagram.com/beforethelightspodcast/Follow the show on Face Book: https://www.facebook.com/beforethelightspodcast/Follow the show on Tik Tok: https://www.tiktok.com/@beforethelightspodcast?lang=enFollow Tommy on Face Book: https://www.facebook.com/tcanale3Rate & Review: https://podcasts.apple.com/us/podcast/before-the-lights/id1501245041Email the host: beforethelightspod@gmail.com

The first round of the 2025 #NBADraft is done… so we've got a HUGE recap and reaction show with Draft Winners & Losers as well as a GRADE for EVER DRAFT PICK! Cooper Flag goes #1, Dylan Harper goes #2… but did the Sixers get faked out at 3? What's with all the Knueppels?!?!? And WHAT IN THE HELL ARE NEW ORLEANS DOING? And WOW was that a mess from Brooklyn…  Plus, we look at where the Aussies - Alex Toohey, Tyrese Proctor, Rocco Zikarsky & Lachlan Olbrich could end up in the2nd round tomorrow!  It's a BIG DRAFT episode of #NBA #straya today!  Plus some YEAH NAHs, Unpopular Opinion of the Day & OUTBACK TAKEHOUSE !!!  We then also look ahead to the 2nd Round and figure out what could happen on Friday!  BIG DAY FOR THE AUSSIES!  So… strap in, lean back & enjoy! … and remember to rate, review & subscribe!  Cheers legends, and thanks for tuning in to the best NBA podcast in the world!! #Onyas...   Love ya guts ledges!!

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

Your calls and texts on the Evander Kane trade. Learn more about your ad choices. Visit megaphone.fm/adchoices

Torres is still on vacation - and with it our "College Hoops Off-Season Grades" continue with the Duke Blue Devils. Duke is coming off a Final Four and just lost Cooper Flagg - but could they actually be BETTER next year? Listen to St. John's off-season grade - HERE ⁠Listen to BYU's off-season grade - HERE⁠ ⁠Listen to Kentucky's off-season grade - HERE⁠⁠ ⁠⁠Listen to NC State's off-season grade - HERE⁠⁠⁠ ⁠⁠⁠⁠Listen to North Carolina's off-season grade - HERE⁠⁠⁠⁠ ⁠⁠⁠⁠Listen to UConn's off-season grade - HERE⁠⁠ Fioboc is giving listeners of the Aaron Torres Pod 20% on their next purchase - for their FULL STORE of beautiful new clothes: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Check out their entire store here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Also, thank you to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Caulipuffs, the healthy, yet delicious snack⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ that is taking over your grocery isle! For more details - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠visit CauliPuffs.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠! Learn more about your ad choices. Visit megaphone.fm/adchoices

This Friday, the Race of the Day is the Grade 3 Penn Mile at Penn National. Tune in as Gino Buccola and Mike Beer offer their analysis.

The Race of the Day for Saturday is the Grade 1 Stephen Foster Stakes at Churchill Downs. Check out the analysis from Gino Buccola and Mike Beer.

Mark chats to Suzanne Breen, Deirdre Heenan, David McCann & Tim Cairns about the past 12 months in local politics.

For the remote community of McCallum on the island's south coast, school's out... forever. We connect with St. Peter's All Grade School's lone teacher and student before the bell rings one last time. (Krissy Holmes with principal and teacher Sarah Carter and graduating Grade 12 student Noah Durnford)

With Torres on vacation - our College Hoops "Off-Season Grades" rolls on but with a twist - today we talk St. John's with a special guest as the NY Post's Zach Braziller talks the Red Storm! The guys talk this year's Big East title, what it's like covering Rick Pitino and the Johnnies ABSURD 2026 roster - is SJU a true title contender?! Listen to BYU's off-season grade - HERE Listen to Kentucky's off-season grade - HERE⁠ ⁠Listen to NC State's off-season grade - HERE⁠⁠ ⁠⁠⁠Listen to North Carolina's off-season grade - HERE⁠⁠⁠ ⁠⁠⁠Listen to UConn's off-season grade - HERE⁠ Fioboc is giving listeners of the Aaron Torres Pod 20% on their next purchase - for their FULL STORE of beautiful new clothes: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Check out their entire store here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Also, thank you to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Caulipuffs, the healthy, yet delicious snack⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ that is taking over your grocery isle! For more details - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠visit CauliPuffs.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠! Learn more about your ad choices. Visit megaphone.fm/adchoices

From a 72-hour labor in rural India to the operating room as a nurse anesthesia resident, Taranjeet Rathore's journey is nothing short of extraordinary. Along with Olivia and Kevin, Taranjeet, a nurse anesthesia resident at National University, opens up about the moment that inspired his career in healthcare, the cultural barriers he's worked to overcome, and his mission to represent underserved voices in nurse anesthesiology. Here's some of what we discuss in this episode:

Featuring an interview with Dr Patrick Y Wen, including the following topics: Glioma classification (0:00) Efficacy and safety of vorasidenib in the management of IDH-mutant gliomas (4:50) Case: A woman in her early 30s with a Grade 2 astrocytoma and an IDH R132H mutation and residual disease postoperatively (11:55) Case: A man in his early 40s experiencing stable disease with vorasidenib after subtotal resection (21:46) Ongoing trial investigating vorasidenib in IDH-mutant gliomas (27:30) Current and emergent strategies for the management of glioblastoma (31:27) Optimizing patient care and quality of life (46:24) CME information and select publications

Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas. CME information and select publications here.

In this episode, Sharona and Bosley sit down for a conversation with Dr. Sean Michael Morris to talk about Critical Digital Pedagogy. What is it? How can we think critically about our grading practices? How do we think critically about AI and it's impact on our grading choices?LinksPlease note - any books linked here are likely Amazon Associates links. Clicking on them and purchasing through them helps support the show. Thanks for your support!https://www.seanmichaelmorris.com/Critical Digital Pedagogy - What Is It?ResourcesThe Center for Grading Reform - seeking to advance education in the United States by supporting effective grading reform at all levels through conferences, educational workshops, professional development, research and scholarship, influencing public policy, and community building.The Grading Conference - an annual, online conference exploring Alternative Grading in Higher Education & K-12.Some great resources to educate yourself about Alternative Grading:The Grading for Growth BlogThe Grading ConferenceThe Intentional Academia BlogRecommended Books on Alternative Grading:Grading for Growth, by Robert Talbert and David ClarkSpecifications Grading, by Linda NilsenUndoing the Grade, by Jesse StommelFollow us on Bluesky, Facebook and Instagram - @thegradingpod. To leave us a comment, please go to our website: www.thegradingpod.com and leave a comment on this episode's page.If you would like to be considered to be a guest on this show, please reach out using the Contact Us form on our website, www.thegradingpod.com.All content of this podcast and website are solely the opinions of the hosts and guests and do not necessarily represent the views of California State University Los Angeles or the Los Angeles Unified School District.Music

Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits  Journal of General Internal Medicine The American Society of Addiction Medicine (ASAM), in collaboration with nine other medical societies and professional associations, developed evidence-based guidelines for tapering benzodiazepine (BZD) medications across various clinical settings. These guidelines were created using a modified GRADE methodology and a clinical consensus process, which included a systematic literature review and several targeted supplemental searches. The guidelines were also revised based on feedback from external stakeholders. Key recommendations include that clinicians should continually assess the risks and benefits of BZD use and tapering. They should engage in shared decision-making with patients and avoid abrupt discontinuation in individuals who may be physically dependent or at risk of withdrawal. Tapering strategies should be personalized and adjusted based on the patient's response. Additionally, clinicians are encouraged to provide psychosocial support to help patients successfully taper off BZDs.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Guest: Roscoe Williams | Programme Director at Read To Rise At Vusizi Primary School in Limpopo, teachers are battling overcrowded classrooms, a critical lack of books, and minimal parental support — all while trying to teach children how to read. With learners expected to switch from Xitsonga to English by Grade 4, the odds are stacked against them. Yet, these educators go above and beyond, creating their own teaching materials, staying after school, and forming reading support groups — all in the hope of breaking the cycle of poverty through literacy. Today, we're joined by an expert working on the frontlines of youth literacy to help us better understand the challenges and solutions in South Africa's ongoing battle against illiteracy. Early Breakfast with Africa Melane is 702’s and CapeTalk’s early morning talk show. Experienced broadcaster Africa Melane brings you the early morning news, sports, business, and interviews politicians and analysts to help make sense of the world. He also enjoys chatting to guests in the lifestyle sphere and the Arts. All the interviews are podcasted for you to catch-up and listen. Thank you for listening to this podcast from Early Breakfast with Africa Melane For more about the show click https://buff.ly/XHry7eQ and find all the catch-up podcasts here https://buff.ly/XJ10LBU Listen live on weekdays between 04:00 and 06:00 (SA Time) to the Early Breakfast with Africa Melane broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3N Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567See omnystudio.com/listener for privacy information.

With Torres on vacation, we're giving you "College Hoops Off-Season Grades" all week! Today, he's talking BYU. With No. 1 recruit AJ Dybantsa, the return of All-Big 12 Richie Saunders and a near perfect roster around them - are the Cougars a true title contender? Listen to Kentucky's off-season grade - HERE Listen to NC State's off-season grade - HERE⁠ ⁠⁠Listen to North Carolina's off-season grade - HERE⁠⁠ ⁠⁠Listen to UConn's off-season grade - HERE Fioboc is giving listeners of the Aaron Torres Pod 20% on their next purchase - for their FULL STORE of beautiful new clothes: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Check out their entire store here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Also, thank you to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Caulipuffs, the healthy, yet delicious snack⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ that is taking over your grocery isle! For more details - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠visit CauliPuffs.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠! Learn more about your ad choices. Visit megaphone.fm/adchoices

Featuring a slide presentation and related discussion from Dr Patrick Y Wen, including the following topics: Classification and pathologic diagnosis of gliomas (0:00) Role of IDH inhibitors in the management of low-grade gliomas (6:37) Ongoing trials and remaining questions in the management of IDH-mutant gliomas (19:53) CME information and select publications

This week on Bronze and Modern Gods:

Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas. CME information and select publications here.

Helen MacDonald and Juan Franco are back to examine the newest in evidence based medicine.   In this episode: gabapentinoids are medications routinely prescribed for treating epilepsy and nerve pain. But, they come with side effects; among them - dizziness, cognitive impairment, and a dent to motor coordination - as well as an increase in suicidal ideation for the patient. Seena Fazel is professor of forensic psychiatry at University of Oxford and joins Juan to discuss a new paper tracking the association of self-harm and gabapentinoids use in Sweden.   Meanwhile, GRADE is a fundamental tool for clinicians to assess the quality of evidence for medical interventions. But, the sheer number of recommendations in the GRADE series can be overwhelming. Gordon Guyatt is a distinguished professor of medicine at McMaster University in Canada, and an early figure in the rise of evidence based medicine. He joins Helen to reflect on the future of EBM, and how the new Core GRADE system can cut through the noise.   Reading list:   1. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden 2. Why Core GRADE is needed: introduction to a new series in The BMJ  

On today's show, our "College Hoops Off-Season Grades" continues with the Kentucky Wildcats! Mark Pope's second Wildcats squad is LOADED - do they have enough to bring home a national title?! Listen to NC State's off-season grade - HERE ⁠Listen to North Carolina's off-season grade - HERE⁠ ⁠Listen to UConn's off-season grade - HERE ⁠⁠ Fioboc is giving listeners of the Aaron Torres Pod 20% on their next purchase - for their FULL STORE of beautiful new clothes: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Check out their entire store here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Also, thank you to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Caulipuffs, the healthy, yet delicious snack⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ that is taking over your grocery isle! For more details - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠visit CauliPuffs.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠! Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's edition of Scott on the Spot, we wonder if grade schools are teaching the right things to students. Are schools, and public schools specifically, spending money in the right places?

Interview with Gregory Martyr, Executive Chairman of Capital Metals PLCOur previous interview: https://www.cruxinvestor.com/posts/capital-metals-lsecmet-unlocking-value-in-high-grade-sri-lankan-mineral-sands-6384Recording date: 16th June 2025Capital Metals (LSE:CMET) has secured a transformative partnership for its Taprobane mineral sands project in Sri Lanka, marking a significant milestone in the company's path to production. The AIM-listed developer announced a 14% investment from Ambeon Capital, a Sri Lankan investment group that brings crucial local expertise and government connections to the high-grade deposit on the country's east coast.The Taprobane project distinguishes itself through exceptional resource quality, featuring 17% grade mineral sands among the world's highest concentrations. Recent aircore drilling has revealed even greater potential, with visual inspections indicating grades exceeding 60% in some areas at depths previously inaccessible through conventional hand auger methods. Executive Chairman Gregory Martyr emphasized the project's economics, noting mining costs of $20 per ton against revenue of $40 per ton, delivering a compelling 100% markup.The strategic value of the Ambeon partnership extends beyond capital injection. Founded by Australian-educated principals combining local market knowledge with international business experience, Ambeon provides direct access to Sri Lankan regulatory channels through its chairman's position on the Board of Investment. This connection proves critical as Capital Metals navigates government requirements for initial raw concentrate exports followed by mandatory value-added processing within two years.Capital Metals plans to commence operations with a $20.9 million concentrate facility utilizing 48 gravity spirals, targeting 125,000 tons of annual production. The company has structured a comprehensive $20 million funding strategy through a Sri Lankan exchange listing, with Ambeon contributing $10 million in equity and arranging $10 million in corporate debt through its banking relationships.The project benefits from established, low-risk processing technology requiring no blasting or chemicals, while the shallow 1.6-meter average depth minimizes operational complexity. With significant drilling inventory yet to be incorporated into resource calculations, the current 10-year mine life could potentially double, supporting the $155 million base case net present value and positioning Capital Metals advantageously in the mineral sands sector.View Capital Metals' company profile: https://www.cruxinvestor.com/companies/capital-metalsSign up for Crux Investor: https://cruxinvestor.com

In this week's episode, Surabhi Veitch and Kim Vopni chat about how we can better educate women about the pelvic and hormonal considerations through our life. Kim shares her personal story, from her initial resistance to childbirth after a Grade 6 sex education class to her pivotal moment witnessing her sister-in-law's empowering birth experience.As an entrepreneur and the Vagina Coach, Kim has been at the forefront of integrating pelvic health into various stages of life. She co-founded Bellies Inc. and developed the Prepare to Push program.Join us for a candid conversation about breaking taboos, empowering women, and redefining pelvic health across all life stages..✨This episode is sponsored by Embodia https://www.embodiaapp.com/ - use code momstrength to save $20 off your first month's Tier 3 membership..Connect with Surabhi:—Find Surabhi on Instagram or Facebook @thepassionatephysio—Website: https://www.thepassionatephysio.ca

Auditeur : - La meilleure amie du compagnon de Benoit vit avec eux, l'ambiance se dégrade Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

On today's show we keep our "College Hoops Off-Season Grades" rolling with the NC State Wolfpack. Has Will Wade built an ACC contender in one off-season? Torres has PLENTY of thoughts! Listen to North Carolina's off-season grade - HERE Listen to UConn's off-season grade - HERE ⁠ Fioboc is giving listeners of the Aaron Torres Pod 20% on their next purchase - for their FULL STORE of beautiful new clothes: ⁠⁠⁠⁠⁠⁠⁠⁠⁠Check out their entire store here⁠⁠⁠⁠⁠⁠⁠⁠⁠ Also, thank you to ⁠⁠⁠⁠⁠⁠⁠⁠⁠Caulipuffs, the healthy, yet delicious snack⁠⁠⁠⁠⁠⁠⁠⁠⁠ that is taking over your grocery isle! For more details - ⁠⁠⁠⁠⁠⁠⁠⁠⁠visit CauliPuffs.com⁠⁠⁠⁠⁠⁠⁠⁠⁠! Learn more about your ad choices. Visit megaphone.fm/adchoices

The Race of the Day for Saturday is the Grade 3 Ohio Derby at Thistledown. Check out the analysis from David Aragona and Gino Buccola.

Weapons Grade Deep Dubstep on Sub FM 17th June 2025 - https://www.sub.fm

Jennifer Dickenson is an author, cancer survivor, lawyer and wellness advocate. In 2011 she was diagnosed with brain cancer, grade 4, glioblastoma. She has been in remission since 2012. Through her experience fighting brain cancer she discovered many healing tools that she now shares with others. When she read Kelly Turner's book Radical Remission in 2014, she actually wept with joy because the tools Turner researched matched exactly with Dickenson's organic path to healing. What a blessing that was. website: www.JenniferDickenson.com Instagram: https://www.instagram.com/jenniferldickenson/ Facebook: https://www.facebook.com/Jennifer.DickensonWrites Linkedin: https://www.linkedin.com/in/jennifer-dickenson-11638b11/ Linktree: https://linktr.ee/jenniferdickenson ______________________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram YouTube __________________________ Connect & Thrive (CAT) is a heart-centered social impact company dedicated to supporting cancer previvors, patients, thrivers, and caregivers. CAT empowers women on their personal healing journeys by connecting them to our Marketplace of reputable practitioners and curated products. Our partners offer evidence-based healing modalities and healthy living products designed to prevent cancer, navigate a cancer diagnosis, and mitigate the risk of recurrence. CAT's mission is to help women CONNECT with a community of partners who can help them THRIVE! Asking for, and accepting, help are signs of strength, not weakness. “In the face of uncertainty, there is nothing wrong with hope.” ~O. Carl Simonton Visit Connect-and-thrive.com 

Send us a textOn this week's episode of the WTR Small-Cap Spotlight, Roshan Pujari, Executive Chairman and CEO of Stardust Power joined Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer of Water Tower Research, and Peter Gastreich, Energy and Sustainability Analyst at Water Tower Research to discuss: 1) the critical need for developing domestic lithium refining capacity in the US, a market which is dominated by imports; 2) plans to build one of the largest battery-grade lithium refineries in the US and strategic advantages of locating in Oklahoma; 3) progress on offtake agreements including 80-100% of phase 1 supply in a non-binding agreement with Sumitomo Corp; 4) Stardust Power's upstream integration strategy and the abundance of lithium reserves and brine assets linked to the oil and gas industry in the US; and 5) the company's financing and capital strategy.  

On today's show our "College Hoops Off-Season Grades" series rolls on with the North Carolina Tar Heels basketball program! With the addition of international star Luka Bogavac, five-star Caleb Wilson and several key transfers - is the Tar Heels roster better than anyone realizes? Also, just how good do the Tar Heels have to be for Hubert Davis to keep his job beyond next season?! Listen to UConn's off-season grade - HERE Fioboc is giving listeners of the Aaron Torres Pod 20% on their next purchase - for their FULL STORE of beautiful new clothes: ⁠⁠⁠⁠⁠⁠⁠⁠Check out their entire store here⁠⁠⁠⁠⁠⁠⁠⁠ Also, thank you to ⁠⁠⁠⁠⁠⁠⁠⁠Caulipuffs, the healthy, yet delicious snack⁠⁠⁠⁠⁠⁠⁠⁠ that is taking over your grocery isle! For more details - ⁠⁠⁠⁠⁠⁠⁠⁠visit CauliPuffs.com⁠⁠⁠⁠⁠⁠⁠⁠! Learn more about your ad choices. Visit megaphone.fm/adchoices

"I'm an advisor for alternative investments," explains Chris Burns about how he connects individual investors with institutional-grade opportunities. The founder of Quema Capital and a broker-dealer with Great Point Capital in Chicago, Chris specializes in helping investors access real estate syndications, development deals, acquisition funds, and private REITs. Tune in to this conversation with host Phil Coover about tax-advantaged investment strategies, including the powerful Roth IRA conversion technique that can reduce tax liability during real estate development's natural J-curve and why Chicago's limited-supply market presents compelling opportunities for both developers and distressed-asset buyers.Connect and Learn More☑️ Chris Burns | LinkedIn☑️ Quema Capital | LinkedIn☑️ Phil Coover | LinkedIn☑️ McGuireWoods | LinkedIn | Facebook | Instagram | X☑️ Subscribe Apple Podcasts | Spotify | Amazon MusicThis podcast was recorded and is being made available by McGuireWoods for informational purposes only. By accessing this podcast, you acknowledge that McGuireWoods makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in the podcast. The views, information, or opinions expressed during this podcast series are solely those of the individuals involved and do not necessarily reflect those of McGuireWoods. This podcast should not be used as a substitute for competent legal advice from a licensed professional attorney in your state and should not be construed as an offer to make or consider any investment or course of action.

BACK TO WINNING WAYS!The defense loked stout even though it was shuffled, the offense created chances but could only finish one, and it was enough.The Orange and Blue grab 3 points after beating a Revolution team unbeaten in their last 9.Adam Kuhn is on vacation so its Adam W and a special guest, his daughter!Listen up!!!!!@TheKingAdRock73 @NinoOne @sbucks67 @crackityFC @ComeOnYouFCC @fccincinnati @Zuhause513 @MLS #AllForCincy #FCCincy #YAL #WestEndBoys

When it comes to cutting-edge skincare, few companies are as rigorously science-backed as Senté. In this episode of The Technology of Beauty, host Dr. Grant Stevens welcomes Zubin Meshginpoosh, President & COO of Senté, to discuss the fusion of pharmaceutical innovation and aesthetic medicine.Join us as Zubin walks us through the origin of Senté's hero molecule — a heparan sulfate analog engineered to deliver therapeutic results through topical application. From calming inflammation and reducing pigmentation to helping patients with rosacea, this biotech-driven approach is delivering results that rival prescription-grade solutions.Tune in to gain insight into Sente's business strategy, clinical commitment, and Zubin's passion for mentorship and patient-centered innovation. It's a compelling look at how small, focused teams are pushing the boundaries of what skincare can achieve — and how technology continues to elevate the patient experience.» Apple Podcasts | https://podcasts.apple.com/us/podcast/technology-of-beauty/id1510898426» Spotify | https://open.spotify.com/show/0hEIiwccpZUUHuMhlyCOAm» Recent episodes | https://www.influxmarketing.com/technology-of-beauty/» Instagram | https://www.instagram.com/thetechnologyofbeauty/» LinkedIn | https://www.linkedin.com/company/the-technology-of-beauty/The Technology of Beauty is produced by Influx Marketing, The Digital Agency for Aesthetic Practices. https://www.influxmarketing.com/Want more aesthetic insights? Subscribe to Next Level Practices, the show where we discuss the ever-changing world of digital marketing and patient acquisition and bring you the latest ideas, strategies, and tactics to help you take your practice to the next level. https://www.influxmarketing.com/next-level-practices/

The Jerry & Jerry Show headlines: How Do You Grade The UVA Chris Pollard Hire? Did UVA AD Carla Williams Make The Right Hire? Pollard Filling Baseball Player & Coaching Roster Is Euro Big Man De Ridder Coming To UVA? UVA Facing Texas In ACC/SEC Challenge How Is UVA Basketball Recruiting Going Now? UVA Football: What To Watch? What Concerns You? How Does UVA Drive Football Fan Engagement? Read Viewer & Listener Comments Live On-Air Jerry Ratcliffe & Jerry Miller were live on The Jerry & Jerry Show! The Jerry & Jerry Show airs live Tuesday from 10:15 am – 11:15 pm on The I Love CVille Network. Watch and listen to The Jerry & Jerry Show on Facebook, Instagram, Twitter, LinkedIn, iTunes, Apple Podcast, YouTube, Spotify, Fountain, Amazon Music, Audible and iLoveCVille.com.

In this episode, Sharona and Boz interview Doug Wilson, principal of Avondale High School in Michigan, about his advice on implementing building-wide grading reform. This discussion touches on ways of being a visionary leader, how to move towards culture change around grades, and advice to administrators (and teachers!) on how to question our practices with an eye towards improving kids' learning. Join us for this fascinating conversation to move forward with grading reform.LinksPlease note - any books linked here are likely Amazon Associates links. Clicking on them and purchasing through them helps support the show. Thanks for your support!Materials from Doug Wilson supporting Grading Reform (Google Folder Link)Building Thinking Classrooms, by Peter LiljedahlResourcesThe Center for Grading Reform - seeking to advance education in the United States by supporting effective grading reform at all levels through conferences, educational workshops, professional development, research and scholarship, influencing public policy, and community building.The Grading Conference - an annual, online conference exploring Alternative Grading in Higher Education & K-12.Some great resources to educate yourself about Alternative Grading:The Grading for Growth BlogThe Grading ConferenceThe Intentional Academia BlogRecommended Books on Alternative Grading:Grading for Growth, by Robert Talbert and David ClarkSpecifications Grading, by Linda NilsenUndoing the Grade, by Jesse StommelFollow us on Bluesky, Facebook and Instagram - @thegradingpod. To leave us a comment, please go to our website: www.thegradingpod.com and leave a comment on this episode's page.If you would like to be considered to be a guest on this show, please reach out using the Contact Us form on our website, www.thegradingpod.com.All content of this podcast and website are solely the...

Louie & Sean are back with BloodHorse Monday ep. 20!They regroup after the Triple Crown by discussing the Breeder's Cup divisions, and hear from the sales at OBS.They close with a discussion of the Grade 2 Chicago Stakes at Churchill, and the Grade 3 Ohio Derby at Thistledown.

Tarina Vlok of Elite Risk stresses the importance of purchase invoices and authorised dealers, highlighting the links between counterfeits and organised crime.

Buckle up with Derek and Karli as they help you chart the ultimate AP roadmap for your students—no GPS required! Whether you're just starting the engine or already cruising, press Play now and enjoy the scenic route to student success on this episode of…Coordinated.Map Out Your Journey with AP: https://apstudents.collegeboard.org/map-your-journey-with-apMost Popular AP Courses by Grade: https://blog.collegeboard.org/popular-ap-courses-gradeAP Courses That Go Well Together: https://blog.collegeboard.org/ap-courses-go-togetherProject Based AP Courses: https://blog.collegeboard.org/what-are-project-based-ap-coursesAP Courses for Majors and Careers: https://blog.collegeboard.org/ap-courses-majors-and-careers-----Register now for the 2025-26 AP Coordinator: Back-to-School WorkshopWatch the Coordinated podcast on YouTube.Subscribe to the AP Coordinator Experience YouTube Channel.Bookmark the AP Coordinator Experience webpage.Watch this video series on how to use AP Registration and Ordering.Join the AP Coordinator Community. Read up at the AP Coordinator Resource Library. Podcast theme song, “Good as Gold,” courtesy of former AP Music Theory student, Jackie Rae.

Jesse grew up as a pastor's kid, surrounded by religion but missing real relationship. Behind closed doors, he battled abuse, trauma, addiction, and spiritual darkness. After a near-fatal overdose and a terrifying encounter with demonic forces, one cry to Jesus changed everything. What happened next will leave you speechless. Listen on Podcast Spotify Podcast ⇨ https://spoti.fi/3RBKdq3Apple Podcast ⇨ https://apple.co/3evzCuuConnect with ushttps://www.facebook.com/delafetestimonieshttps://www.instagram.com/delafetestimonies/Credits:Testimony by Jesse HernándezDirected by Eric Villatoro Interviewed by Eric Villatoro Edited By Darvin RamirezAudio Mixed by Paul Nicholas Testimony Recorded in Houston, TexasDelafé Testimonies is a global evangelistic project with the mission of creating the world's largest archive of Jesus testimonies until His return. Chapters00:00 Introduction00:21 Growing Up In a Strict Home as A Pastors Kid 02:21 Believing God Was an Angry God 04:01 Experiencing Sexual Abuse As a Child05:52 Being Exposed To Sexual Things in The 5th Grade 07:55 The Start Of My Sexual Brokenness08:44 Discovering My Passion For Dance 11:13 Hiding My New Found Passion From My Parents 14:38 Attending My First Rave 17:38 Trying Ecstasy For The First Time 20:15 Feeling The Love I Desired Through Drugs 23:49 Searching For Freedom Within Drugs 26:44 My Parents Discover My Drug Use 29:46 I See a Vision While on Drugs 32:24 No Longer Finding Joy Through Drugs 35:40 My Intro To a Harder Drug39:12 Experiencing Another Vision While On Hard Drugs 42:14 Hearing The Audible Voice of God 44:01 I Decide to Move Back In With My Parents 46:28 Going To Church But Living My Way 49:57 I Cry Out To God and He Shows Me a Vision53:45 The Holy Spirit Came Into My Life 58:02 Prayer 58:28 My Relationship With My Parents Today 1:01:02 Who is Jesus to You?1:01:25 Final Words My Drug Addiction Was BROKEN When JESUS Told Me THIS...

Welcome to Episode #162 of the Talking Shop Podcast, recorded June 16, 2025 — where we cover the latest hobby headlines, viral moments, and the decisions collectors face every week.In this episode, we kick things off with Bruce the Bat Dog getting called up to the Nationals for a one-game MLB debut. It's baseball and golden retrievers—what's more American than that?Then, just in time for Father's Day, a viral post makes the rounds: a wife completely loses it after finding out her husband spent thousands on sports cards. It's funny until it's… kind of real.In Hobby News, we cover:The GameStop–PSA acquisition rumor that turned out to be falseLogan Paul's first WWE trading card — a 1/1 dual auto with John CenaJac Caglianone joining a live break after his Superfractor gets pulledA fresh look at the ongoing online breakers vs. card shop debateAnd a collector building a full stadium-themed card collectionWe close the episode with our main story: a viral grading decision tree that walks through when it actually makes sense to grade a card. If you've ever second-guessed sending something in, this one's for you.

Another loaded Players' Podcast coming to the airwaves this week starting with a look at Woodbine's Late Pick 4 sequence for Saturday (June 14) with host Mikee P joined by handicapper Jackson Muniz.Later, PTF from his abode abroad ahead of Royal Ascot ganders alongside JK at the All-Stakes Pick 5 & Pick 4 sequence on Haskell Preview Day (Saturday, June 14) at Monmouth Park. Haskell Preview Day also is the focus of a special contest over at horsetourneys.com, where for just $1 you can enter to play for a chance to earn a seat for the Haskell Day Betting Challenge next month.Mikee P hosts the concluding segment and has Alex Henry back to look at the last Grade 1 of the 2025 Spring Session in Japan, the Takarazuka Kinen at Hanshin Racecourse.

Torres starts his College Hoops "Off-Season Grades" series with UConn - after a disappointing season, what did Dan Hurley do to ensure that the Huskies bounce back?! And does Hurley again have a title contender?! Fioboc is giving listeners of the Aaron Torres Pod 20% on their next purchase - for their FULL STORE of beautiful new clothes: ⁠⁠⁠⁠⁠⁠⁠⁠⁠Check out their entire store here⁠⁠⁠⁠⁠⁠⁠⁠⁠ Also, thank you to ⁠⁠⁠⁠⁠⁠⁠⁠⁠Caulipuffs, the healthy, yet delicious snack⁠⁠⁠⁠⁠⁠⁠⁠⁠ that is taking over your grocery isle! For more details - ⁠⁠⁠⁠⁠⁠⁠⁠⁠visit CauliPuffs.com⁠⁠⁠⁠⁠⁠⁠⁠⁠! Learn more about your ad choices. Visit megaphone.fm/adchoices